HR+/HER2- DUCTAL AND LOBULAR BREAST CANCER
Clinical trials for HR+/HER2- DUCTAL AND LOBULAR BREAST CANCER explained in plain language.
Never miss a new study
Get alerted when new HR+/HER2- DUCTAL AND LOBULAR BREAST CANCER trials appear
Sign up with your email to follow new studies for HR+/HER2- DUCTAL AND LOBULAR BREAST CANCER, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Radioactive drug takes aim at Hard-to-Treat cancers
Disease control Recruiting nowThis early-stage trial is testing a new radioactive drug (177Lu-DFC413) to see if it is safe and can shrink tumors in people with advanced solid cancers like pancreatic, lung, breast, colorectal, and sarcoma. About 180 adults whose cancer has progressed after standard treatments …
Matched conditions: HR+/HER2- DUCTAL AND LOBULAR BREAST CANCER
Phase: PHASE1 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New 'Smart Bomb' radiation therapy targets multiple cancers in early trial
Disease control Recruiting nowThis early-stage trial is testing a new type of targeted radiation therapy for people with advanced pancreatic, lung, breast, or colorectal cancers. The treatment uses a radioactive drug that seeks out cancer cells to deliver radiation directly, aiming to kill them while sparing …
Matched conditions: HR+/HER2- DUCTAL AND LOBULAR BREAST CANCER
Phase: PHASE1 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC